Global Fibromyalgia Treatment Market Research Report 2022
Fibromyalgia syndrome (FS) is a non-articular rheumatic disorder characterized by pain and stiffness of the musculoskeletal system and tenderness in specific sites.Fibromyalgia syndrome can be secondary to trauma, a variety of rheumatic diseases, such as osteoarthritis, rheumatoid arthritis and a variety of non-rheumatic diseases (such as hypothyroidism, malignant tumors).
Due to the COVID-19 pandemic, the global Fibromyalgia Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Fibromyalgia Treatment market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Fibromyalgia Treatment landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Antidepressants accounting for % of the Fibromyalgia Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals Pharmacies segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Fibromyalgia Treatment include Eli Lilly and Company, Pfizer, Novartis AG, Allergan, Aptinyx, Prismic Pharmaceuticals, Innovative Med Concepts, Intec Pharma Ltd. and Astellas Pharma, etc. In terms of revenue, the global 3 largest players have a % market share of Fibromyalgia Treatment in 2021.
This report focuses on Fibromyalgia Treatment volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Fibromyalgia Treatment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Fibromyalgia Treatment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Antidepressants
Anticonvulsants
Muscle Relaxants
Narcotic Analgesics
Non-narcotic Analgesics
Segment by Application
Hospitals Pharmacies
Clinic Pharmacy
Retail Drug Stores
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Eli Lilly and Company
Pfizer
Novartis AG
Allergan
Aptinyx
Prismic Pharmaceuticals
Innovative Med Concepts
Intec Pharma Ltd.
Astellas Pharma
Savella
Sun Pharmaceutical Industries
Mylan NV
Teva Pharmaceutical Industries
Daiichi Sankyo
Forest Pharmaceuticals
Meiji Seika Pharma
Tonix Pharmaceuticals
Theravance Biopharma
Due to the COVID-19 pandemic, the global Fibromyalgia Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Fibromyalgia Treatment market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Fibromyalgia Treatment landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Antidepressants accounting for % of the Fibromyalgia Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals Pharmacies segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Fibromyalgia Treatment include Eli Lilly and Company, Pfizer, Novartis AG, Allergan, Aptinyx, Prismic Pharmaceuticals, Innovative Med Concepts, Intec Pharma Ltd. and Astellas Pharma, etc. In terms of revenue, the global 3 largest players have a % market share of Fibromyalgia Treatment in 2021.
This report focuses on Fibromyalgia Treatment volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Fibromyalgia Treatment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Fibromyalgia Treatment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Antidepressants
Anticonvulsants
Muscle Relaxants
Narcotic Analgesics
Non-narcotic Analgesics
Segment by Application
Hospitals Pharmacies
Clinic Pharmacy
Retail Drug Stores
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Eli Lilly and Company
Pfizer
Novartis AG
Allergan
Aptinyx
Prismic Pharmaceuticals
Innovative Med Concepts
Intec Pharma Ltd.
Astellas Pharma
Savella
Sun Pharmaceutical Industries
Mylan NV
Teva Pharmaceutical Industries
Daiichi Sankyo
Forest Pharmaceuticals
Meiji Seika Pharma
Tonix Pharmaceuticals
Theravance Biopharma
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
